GLP-1 Medication Use for Type 2 Diabetes Has Soared.

JAMA

Manager and Senior Medical Illustrator, Editorial Graphics, JAMA and JAMA Network.

Published: September 2024

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2024.18219DOI Listing

Publication Analysis

Top Keywords

glp-1 medication
4
medication type
4
type diabetes
4
diabetes soared
4
glp-1
1
type
1
diabetes
1
soared
1

Similar Publications

Introduction: In diabetics, glucagon-like peptide 1 (GLP-1) receptor agonists (RA) may protect against microvascular alterations and oxidative stress, both of which have been implicated in glaucoma. Multiple studies suggest a possible relation between GLP-1 RA use and the development of glaucoma. This study performs a systematic review of the literature regarding the incidence of glaucoma development in type 2 diabetes patients treated with GLP-1 receptor agonists compared to a control group.

View Article and Find Full Text PDF

GLP-1 and IL-6 regulates obesity in the gut and brain.

Life Sci

December 2024

School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China. Electronic address:

Obesity is a chronic metabolic disease characterized by excessive nutrient intake leading to increased subcutaneous or visceral fat, resulting in pathological and physiological changes. The incidence rate of obesity, an important form of metabolic syndrome, is increasing worldwide. Excess appetite is a key pathogenesis of obesity, and the inflammatory response induced by obesity has received increasing attention.

View Article and Find Full Text PDF

Background: Bariatric surgery is very effective in long-term weight management. The present study was undertaken to investigate the short-term effects of sleeve gastrectomy (SG) and of Roux-en-Y gastric bypass (RYGB) on (a) gastrointestinal (GI) motility, that is gastric emptying and oro-cecal transit time and (b) secretion of regulatory gut peptides and (c) their interrelationship.

Methods: Prospective single-centre study in which we assessed gastric emptying, oro-cecal transit time and gut peptide release in 28 severely obese individuals before and 2, respectively, 12 months after bariatric surgery (either SG or RYGB).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!